Deferasirox
| Evidence Level: L4 | Predicted Indications: 5 |
Table of Contents
Deferasirox: From Iron Overload to HIV Infectious Disease
One-Sentence Summary
Deferasirox is an iron chelator; this evidence pack does not document its originally licensed indication in detail, though supporting literature within the pack references its established use in iron overload/transfusion-dependent conditions. The TxGNN model predicts potential relevance to HIV infectious disease, but this is currently supported only by 2 mechanistic/preclinical publications and no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (drug class: iron chelator) |
| Predicted New Indication | HIV infectious disease |
| TxGNN Prediction Score | 99.40% |
| Evidence Level | L4 |
| UK Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on the information that is available, deferasirox is an iron chelator, and the supporting literature identified for this prediction centres on iron metabolism rather than a direct antiviral mechanism.
The strongest mechanistic signal comes from a 2021 in vitro study showing that endolysosomal iron levels restrict HIV-1 Tat-mediated LTR transactivation by increasing Tat oligomerisation and β-catenin expression — suggesting that iron chelation could, in principle, modulate this pathway. However, this study did not test deferasirox directly as the intervention; it examined cellular iron status more broadly. The second reference (2006) is a brief new-drug-approval notice covering deferasirox alongside three unrelated drugs and contains no HIV-specific content.
Overall, the biological rationale is plausible but indirect: it rests on an inferred link between iron restriction and a step in HIV-1 transcription, rather than any direct experimental or clinical evidence of deferasirox activity against HIV. This corresponds to a mechanistic/preclinical evidence tier (L4), not a clinical signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34550543 | 2021 | Mechanistic/In vitro | Journal of NeuroVirology | Endolysosomal iron levels restrict HIV-1 Tat-mediated LTR transactivation via effects on Tat oligomerisation and β-catenin expression; iron status affects HIV-1 replication in vitro, but deferasirox itself was not the study intervention |
| 16529348 | 2006 | News/Drug approval notice | Journal of the American Pharmacists Association (JAPhA) | Brief new-drug notice covering deferasirox’s original approval; no HIV-related content |
UK Market Information
No UK marketing authorisation is currently recorded for deferasirox in this evidence pack (0 licenses; market status: not marketed).
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
(Note: key warnings, contraindications, and drug interaction data are marked as a Blocking data gap in this evidence pack — sourcing TFDA/SmPC labelling is required before any safety-based screening can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The HIV indication is supported only by one indirect in vitro mechanistic study and no clinical trials, placing it at evidence level L4. Combined with the absence of any UK marketing authorisation and a Blocking-severity gap in safety/label data, there is insufficient basis to advance beyond initial screening (decision stage S0).
To proceed, the following is needed:
- Deferasirox SmPC/label data (warnings, contraindications, DDIs) — currently a Blocking gap
- Confirmed mechanism of action data from DrugBank or equivalent source
- A direct interventional study (in vitro or clinical) testing deferasirox against HIV-1, rather than iron-status studies alone
- Clarification of original licensed indication(s) for this compound, not currently captured in the evidence pack
Note: four lower-ranked candidates (chronic HCV infection, a rare neurodevelopmental disorder, an obsolete hyperlipidaemia label, and dermatofibrosarcoma protuberans) were also screened at L4–L5 evidence levels; all were scored Hold and are not detailed here as they fall outside the top-ranked prediction this report format covers.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.